73 completed. 73 Phase 2, 16 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 73 | Completed 73 |
| Phase 1 | 16 | Completed 16 |
| Phase 3 | 3 | Completed 3 |
Follow Streptococcal Infections: new trials by email Literature Review of Streptococcal Infections trials Research Report on Streptococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 480 | 2025-09-11 | 2026-07-27 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Children PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 2 | Completed | Pfizer | 225 | 2024-07-30 | 2026-03-11 |
| Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3 - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 992 | 2024-04-20 | 2026-08-17 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-11-06 |
| A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers mPnC candidate, mPnC control - Healthy Participants | Phase 2 | Completed | Pfizer | 105 | 2023-11-08 | 2025-05-08 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 802 | 2023-03-29 | 2025-09-11 |
| A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals. p*17-K4S2, J8-K4S2, Rabavert vaccine - Group A Streptococcal Infection | Phase 1 / Phase 2 | Completed | University of Alberta | 30 | 2022-11-07 | 2025-05-28 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants AFX3772, Prevnar 13, Prevnar 20 - Pneumonia, Bacterial, Pneumococcal Infections | Phase 2 | Completed | GlaxoSmithKline | 388 | 2022-06-16 | 2026-10-09 |
| Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women GBS-NN/NN2 Vaccine, Placebo - Group B Streptococcal Infection | Phase 2 | Completed | Minervax ApS | 269 | 2022-02-17 | 2025-06-11 |
| Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment - Drug Use, Opioid-use Disorder | Phase 2 | Completed | Laura Fanucchi | 71 | 2021-03-16 | 2026-04-28 |
| Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV GBS-NN/NN2, Placebo - Group B Streptococcal Infection | Phase 2 | Completed | Minervax ApS | 200 | 2020-11-19 | 2026-07-14 |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6) - Group B Streptococcal Infections | Phase 2 | Completed | Pfizer | 151 | 2020-02-11 | 2021-10-13 |
| A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) V116, Pneumovax™23 - Pneumonia, Pneumococcal | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 600 | 2019-12-06 | 2022-09-16 |
| Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. Prevenar13 (PCV13) and Pneumovax (PPS23), Placebo / Pneumovax (PPS23), Blood sample - Splenectomised Patients | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 39 | 2019-08-27 | 2026-07-01 |
| A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine ASP3772, PCV13, PPSV23 - Pneumonia, Bacterial, Healthy Volunteers | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 630 | 2019-01-24 | 2023-12-21 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis Daptomycin - Pneumococcal Meningitis | Phase 2 | Completed | Centre Hospitalier Universitaire Dijon | 112 | 2018-06-07 | 2024-10-01 |
| A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants LBVE, Prevnar13 - Pneumococcal Infection | Phase 2 | Completed | LG Chem | 230 | 2018-05-25 | 2019-08-22 |
Showing 20 of 73. Sign in to see all of them.
Pneumococcal Infections (35) · Impetigo (8) · Pneumonia (5) · Pneumonia, Pneumococcal (5) · Cellulitis (4) · Haemophilus Infections (4) · Abscess (3) · Bacterial Infections (3) · Endocarditis, Subacute Bacterial (2) · Erysipelas (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Pneumonia, Bacterial (2) · Rheumatic Heart Disease (2)
Bacterial Infections and Mycoses (73) · Gram-Positive Bacterial Infections (71) · Infections (71) · Bacterial Infections (70) · Skin and Connective Tissue Diseases (12) · Skin Diseases (11) · Skin Diseases, Bacterial (11) · Skin Diseases, Infectious (11) · Staphylococcal Infections (10) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Respiratory Tract Infections (9) · Staphylococcal Skin Infections (8) · Pathologic Processes (6)
13-valent pneumococcal vaccine (19) · 23-valent pneumococcal capsular polysaccharide vaccine (7) · Pneumococcal Vaccines (7) · Heptavalent Pneumococcal Conjugate Vaccine (5) · PHiD-CV vaccine (5) · Saline Solution (3) · Sodium Chloride (3) · Vaccines, Combined (3) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (3) · Daptomycin (2) · 10-valent pneumococcal conjugate vaccine (1) · Blood Specimen Collection (1) · Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · CRM197 (non-toxic variant of diphtheria toxin) (1)
GlaxoSmithKline (11) · Merck Sharp & Dohme LLC (8) · Pfizer (8) · Assistance Publique - Hôpitaux de Paris (3) · LEO Pharma (2) · Lytix Biopharma AS (2) · Minervax ApS (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · NovaBay Pharmaceuticals, Inc. (2) · Novartis Vaccines (2) · PATH (2) · Reinovax Biologics Co., LTD (2) · CIHR Canadian HIV Trials Network (1) · Cellceutix Corporation (1) · Centre Hospitalier Universitaire Dijon (1)
United States (28) · South Africa (7) · Canada (5) · China (4) · Czechia (4) · Belgium (3) · France (3) · Germany (3) · Poland (3) · Spain (3) · Australia (2) · Denmark (2) · Dominican Republic (2) · Finland (2) · Israel (2)
Philippe Prokocimer, MD (2) · Almena L Free, MD (1) · Amar Safdar, MD (1) · Benjamin Rossi, MD (1) · Cornelia Oostvogels (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1) · Ed Clarke, MD PhD (1) · Fiona M Russell, FRACP (1)
PMID 30689507, PMID 15882530, PMID 17391816, PMID 18470901, PMID 18799552, PMID 20199764, PMID 20206670, PMID 20435707, PMID 20943882, PMID 21044669, PMID 21537018, PMID 21539882, PMID 22353593, PMID 23300160, PMID 23535358, PMID 23967126, PMID 26409812, PMID 26869376, PMID 26942345, PMID 27139805, PMID 27530088, PMID 28917688, PMID 29029127, PMID 29279281, PMID 29374589, PMID 29559167, PMID 30244873, PMID 30427749, PMID 30648919, PMID 31843266, PMID 32169390, PMID 32639460, PMID 32716500, PMID 32891191, PMID 33661716, PMID 33767093, PMID 34525007, PMID 35690500, PMID 36116461, PMID 37491088, PMID 38190492, PMID 38360475, PMID 39563457, PMID 39883948, PMID 40523378, PMID 41386262
2023 (2), 2009 (1), 2014 (1), 2016 (1), 2018 (1), R01DA048892 (1)